Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | EBP | Q15125 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864302 | 0.86 | SLC2A1 (0.57) | SLC2A1EBPSIGMAR1CYP1A2LTA4H | |
| SCHEMBL2331536 | 0.84 | SLC2A1 (0.47) | SLC2A1EBPSIGMAR1CYP1A2LTA4H | |
| SCHEMBL2425061 | 0.83 | EBP (0.55) | EBPSIGMAR1CYP1A2LTA4HCYP2D6 | |
| SCHEMBL2426949 | 0.83 | EBP (0.55) | EBPSIGMAR1CYP1A2LTA4HCYP2D6 | |
| SCHEMBL9706125 | 0.80 | EBP (0.72) | EBPSIGMAR1CYP1A2LTA4HCYP2D6 | |
| SCHEMBL12015816 | 0.79 | KDM4E (0.67) | EBPSIGMAR1CYP1A2LTA4HCYP2D6 | |
| Coralgil SCHEMBL317407 | 0.78 | EBP (0.61) | EBPSIGMAR1CYP1A2LTA4HCYP2D6 | |
| Coralgil SCHEMBL26128795 | 0.78 | EBP (0.61) | EBPSIGMAR1CYP1A2LTA4HCYP2D6 | |
| Coralgil SCHEMBL29989837 | 0.76 | EBP (0.59) | EBPSIGMAR1CYP1A2LTA4HCYP2D6 | |
| SCHEMBL9827594 | 0.76 | EBP (0.59) | EBPSIGMAR1CYP1A2LTA4HCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619184-B1 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20140357673-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UNIV MICHIGAN (US) | 2014-12-04 | — | — | US | disclosed |
| US-8809377-B2 | Deubiquitinase inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-08-19 | — | — | US | disclosed |
| WO-2012040527-A2 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120077806-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357673-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UCHL1, USP2, USP1 | SLC2A1 4639/4885EBP 3246/4885SIGMAR1 4115/4885 |
| US-20120077806-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UCHL1, USP2, USP1 | SLC2A1 4639/4885EBP 3246/4885SIGMAR1 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.